NEWM&A

Biogen (BIIB) Buy Rating Reiterated After RayThera Acquisition

Published on 6/18/2026

#BIIB#M&A#Needham
Biogen (BIIB) Buy Rating Reiterated After RayThera Acquisition

AI Summary

Needham has reiterated a Buy rating on Biogen (BIIB) following its acquisition of RayThera. This acquisition aligns with Biogen's strategic focus on expanding its offerings in neurodegenerative diseases. Needham has highlighted the potential for increased market share and revenue growth post-acquisition. Such strategic moves may positively influence investor confidence and stock performance for Biogen.

Source: Read original article (opens in new tab)

Related News

Italy Neutral on Monte Paschi (BMPS), Plans Stake Sale Through Placement
M&A

Italy Neutral on Monte Paschi (BMPS), Plans Stake Sale Through Placement

Jun 18

Arcutis Biotherapeutics (ARQT) Form 144 Filing on June 17
M&A

Arcutis Biotherapeutics (ARQT) Form 144 Filing on June 17

Jun 18

Obayashi (OBAYF) to Acquire Multiplex for $526 Million
M&A

Obayashi (OBAYF) to Acquire Multiplex for $526 Million

Jun 18

Portland Railroad Crossing Merger Information to Regulators Delayed
M&A

Portland Railroad Crossing Merger Information to Regulators Delayed

Jun 18